Navigation Links
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
Date:3/12/2008

w.cadencepharm.com" target="_new">http://www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Forward-looking Statements

Cadence cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. These forward-looking statements include statements regarding: the timeframes in which Cadence expects to initiate, complete enrollment in, and disclose results from its clinical trials of Acetavance and Omigard, and the timeframes for filing submissions with regulatory authorities seeking marketing authorizations for these product candidates; statements regarding the effects of management changes; Cadence's projected operating expenses and cash balances for 2008; and the adequacy of the company's funding to advance its product candidates through to NDA submissions. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Cadence's business, including, without limita
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
2. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
3. ISTA Pharmaceuticals to Present at the Cowen & Company 28th Annual Health Care Conference
4. SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results
5. Onyx Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
6. Idenix Pharmaceuticals to Present at the Eleventh Annual Lehman Brothers Global Healthcare Conference
7. Drinking Water Association Discusses Pharmaceuticals in Water
8. Genesis Pharmaceuticals Changes Auditors
9. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
10. Statement from American Water Works Association on Associated Press Story on Pharmaceuticals in Drinking Water
11. Vion Pharmaceuticals Regains NASDAQ Listing Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... , , , , ... (Nasdaq: WCRX ) today announced its results for the ... 30, 2009 increased 7.1% to $250.8 million over the prior year ... net sales of DORYX, LOESTRIN 24 FE and ESTRACE Cream which ...
... - Quarter Marked by Launch of RYZOLT(TM) in U.S. -, ... Novel Trazodone, ... , , LAVAL, QC, Aug. 7 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: ... figures are in Canadian dollars unless otherwise stated. , "The second quarter of 2009 was highlighted ...
... ... and technology solutions, today announced the opening of a Chicago field office to better support ... ... Marathon Health, a leading provider of onsite employee health services and technology solutions, ...
... ... vice president for consulting. , ... St. Louis, MO (Vocus) -- Navvis & Company announces the appointment ... the firm and its clients extensive experience and expertise in health system operations, strategic ...
... expensive patients need fewer health care resources and cost insurers ... care team that tracks their health and offers regular support, ... Bloomberg School of Public Health. The research, published in the ... the first eight months of a randomized controlled trial, patients ...
... , WASHINGTON, Aug. 6 Lung Cancer Alliance ... another $11.8 million of the $20 million lung cancer research ... Research Program (CDMRP). , , (Logo: ... The solicitation invited researchers to compete for $10.5 ...
Cached Medicine News:Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 18Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 2Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 3Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 4Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 5Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 6Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 7Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 8Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 9Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 10Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 11Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 12Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 13Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 14Health News:Labopharm Reports Results for Second Quarter Fiscal 2009 15Health News:Marathon Health Expands Midwest Presence 2Health News:Cleveland Joins Navvis & Company 2Health News:Guided care reduces cost of health care for older persons with chronic conditions 2Health News:LCA Announces More Requests for Bids on Lung Cancer Research Programs Funded Through the Department of Defense 2
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and ... "TEN", Noble Financial Capital Markets, Tenth Annual Equity ... a corporate presentation to prospective corporate partners and ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ... of $2.92 per share, net to the seller in ...
(Date:1/14/2014)... FRAMINGHAM, Mass. , Jan. 14, 2014 /PRNewswire/ ... HTWR ), a leading innovator of less ... the treatment of advanced heart failure, today announced ... of 2013 will be approximately $53 million, bringing ... "Our full-year revenue growth of 87% ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... DIEGO and MONTPELLIER, France, Dec. 2, 2011  MedinCell, ... technology, will be exploring partnerships for key companion ... the Terrapinn World Animal Health Congress in Kansas ... polymer technology offers exceptional control over the duration ...
... PHILADELPHIA, Dec. 2, 2011 Shire plc (LSE: SHP, ... company, announces that it has reached an agreement with ... the U.S. Food and Drug Administration (FDA) to conduct ... ProAmatine® (midodrine HCl), a medicine approved in 1996 under ...
Cached Medicine Technology:MedinCell to Explore Controlled-Release Drug Delivery Partnerships at the World Animal Health Congress 2ProAmatine® (midodrine HCl) Update: Path Forward Agreed 2ProAmatine® (midodrine HCl) Update: Path Forward Agreed 3ProAmatine® (midodrine HCl) Update: Path Forward Agreed 4
... System supports approaches to Admitting/Discharge/Transfer ... record keeping functions using a ... facilities and cut across institutional ... community clinics, physician, agency, nursing ...
... Dairylands Clinical Information Management ... suite of integrated applications ... departments and automate administrative ... The applications allow organizations ...
... include a Patient Face Sheet, ... many as six custom tabs, ... information is important for you ... Import Manager utility lets you ...
... WEBeDoctor® Physician-office® is an ... physicians, (Solo practice, group ... to complete their normal ... It is a front ...
Medicine Products: